Site Map - IAVI - International AIDS Vaccine Initiative

Induction of circulating T follicular helper cells and regulatory T cells correlating with HIV 1 gp120 variable loop antibodies by a subtype C prophylactic vaccine tested in a Phase I trial in India

Evaluation of a mosaic HIV 1 vaccine in a multicentre randomised double blind placebo controlled phase 1 2a clinical trial APPROACH and in rhesus monkeys NHP 13 19

Cell surface ectodomain integrity of a subset of functional HIV 1 envelopes is dependent on a conserved hydrophilic domain containing region in their C terminal tail

Frequencies of Circulating Th1 Biased T Follicular Helper Cells in Acute HIV 1 Infection Correlate with the Development of HIV Specific Antibody Responses and Lower Set Point Viral Load

Antisense Derived HIV 1 Cryptic Epitopes Are Not Major Drivers of Viral Evolution during the Acute Phase of Infection

Prediction of extended high viremia among newly HIV 1 infected persons in sub Saharan Africa

Risk of heterosexual HIV transmission attributable to sexually transmitted infections and non specific genital inflammation in Zambian discordant couples 1994 2012

Targeting the HIV 1 spike and co receptor with bi and trispecific antibodies for single component broad inhibition of entry

Strategies for a multi stage neutralizing antibody based HIV vaccine

Co evolution of HIV Envelope and Apex Targeting Neutralizing Antibody Lineage Provides Benchmarks for Vaccine Design

Differences in acute retroviral syndrome by HIV 1 subtype in a multicentre cohort study in Africa

Structural and immunologic correlates of chemically stabilized HIV 1 envelope glycoproteins

Ligand accessibility to the HIV 1 Env co receptor binding site can occur prior to CD4 engagement and is independent of viral tier category

Cleavage Independent HIV 1 Trimers From CHO Cell Lines Elicit Robust Autologous Tier 2 Neutralizing Antibodies

Epitope based vaccine design yields fusion peptide directed antibodies that neutralize diverse strains of HIV 1

Structure of a cleavage independent HIV Env recapitulates the glycoprotein architecture of the native cleaved trimer

Elicitation of Neutralizing Antibodies Targeting the V2 Apex of the HIV Envelope Trimer in a Wild Type Animal Model

Protection against a mixed SHIV challenge by a broadly neutralizing antibody cocktail

Evaluation of HIV 1 rapid tests and identification of alternative testing algorithms for use in Uganda

Improving the Immunogenicity of Native like HIV 1 Envelope Trimers by Hyperstabilization

Global site specific N glycosylation analysis of HIV envelope glycoprotein

An open label cluster randomised trial to evaluate the effectiveness of a counselling intervention on linkage to care among HIV infected patients in Uganda Study design

Lack of decline in hepatitis C virus incidence among HIV positive men who have sex with men during 1990 2014

Schistosoma mansoni and HIV acquisition in fishing communities of Lake Victoria Uganda a nested case control study

Detection and treatment of Fiebig stage I HIV 1 infection in young at risk women in South Africa a prospective cohort study

Estimating HIV Incidence in Populations Using Tests for Recent Infection Issues Challenges and the Way Forward

Structure based design of native like HIV 1 envelope trimers to silence non neutralizing epitopes and eliminate CD4 binding

Perspective APOBEC mutagenesis in drug resistance and immune escape in HIV and cancer evolution

A Neutralizing Antibody Recognizing Primarily N Linked Glycan Targets the Silent Face of the HIV Envelope

Elevated expression impairs HIV control through inhibition of NKG2A expressing cells

Envelope proteins of two HIV 1 clades induced different epitope specific antibody response

Utility of Different Adherence Measures for PrEP Patterns and Incremental Value

cGMP production and analysis of BG505 SOSIP 664 an extensively glycosylated trimeric HIV 1 envelope glycoprotein vaccine candidate

Synthetic multivalent V3 glycopeptides display enhanced recognition by glycan dependent HIV 1 broadly neutralizing antibodies

Risky Sex and HIV Acquisition Among HIV Serodiscordant Couples in Zambia 2002 2012 What Does Alcohol Have To Do With It

Immunoglobulin G1 Allotype Influences Antibody Subclass Distribution in Response to HIV gp140 Vaccination

Decoding the human immune system to transform the future of global disease prevention and control

Brief counselling after home based HIV counselling and testing strongly increases linkage to care a cluster randomized trial in Uganda

Pregnancy and HIV Disease Progression in an Early Infection Cohort from Five African Countries

Broad neutralization response in a subset of HIV 1 subtype C infected viraemic non progressors from southern India

Residue centric modeling and design of saccharide and glycoconjugate structures

The Tetrameric Plant Lectin BanLec Neutralizes HIV through Bidentate Binding to Specific Viral Glycans

Hidden Lineage Complexity of Glycan Dependent HIV 1 Broadly Neutralizing Antibodies Uncovered by Digital Panning and Native Like gp140 Trimer

Computational analysis of antibody dynamics identifies recent HIV 1 infection

Defining HIV 1 transmission clusters based on sequence data

Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques

An HIV 1 antibody from an elite neutralizer implicates the fusion peptide as a site of vulnerability

A Phase 1 Human Immunodeficiency Virus Vaccine Trial for Cross Profiling the Kinetics of Serum and Mucosal Antibody Responses to CN54gp140 Modulated by Two Homologous Prime Boost Vaccine Regimens

Quantification of the Impact of the HIV 1 Glycan Shield on Antibody Elicitation

The Landscape of Targeted Immune Responses in the HIV 1 Vaccine Field

Viral load criteria and threshold optimization to improve HIV incidence assay characteristics

Rapid elicitation of broadly neutralizing antibodies to HIV by immunization in cows

Neutralizing antibody affords comparable protection against vaginal and rectal simian human immunodeficiency virus challenge in macaques

Effect of Schistosoma mansoni Infection on Innate and HIV 1 Specific T Cell Immune Responses in HIV 1 Infected Ugandan Fisher Folk

Adenovirus based HIV 1 vaccine candidates tested in efficacy trials elicit CD8 T cells with limited breadth of HIV 1 inhibition

Cryopreservation related loss of antigen specific IFN producing CD4 T cells can skew immunogenicity data in vaccine trials Lessons from a malaria vaccine trial substudy

Couples voluntary HIV counseling and testing provider training evaluation Zambia

HIV Envelope Glycoform Heterogeneity and Localized Diversity Govern the Initiation and Maturation of a V2 Apex Broadly Neutralizing Antibody Lineage

Infection Staging and Incidence Surveillance Applications of High Dynamic Range Diagnostic Immuno Assay Platforms

High Density Array of Well Ordered HIV 1 Spikes on Synthetic Liposomal Nanoparticles Efficiently Activate B Cells

Clinical and public health implications of acute and early HIV detection and treatment a scoping review

Holes in the Glycan Shield of the Native HIV Envelope Are a Target of Trimer Elicited Neutralizing Antibodies

HIV 1 Cross Reactive Primary Virus Neutralizing Antibody Response Elicited by Immunization in Nonhuman Primates

Broadly Neutralizing Antibodies to HIV and Their Role in Vaccine Design

HIV Broadly Neutralizing Antibodies Taking Good Care Of The 98

Targeted N glycan deletion at the receptor binding site retains HIV Env NFL trimer integrity and accelerates the elicited antibody response

HIV 1 transmission networks in high risk fishing communities on the shores of Lake Victoria in Uganda A phylogenetic and epidemiological approach

Status of vaccine research and development of vaccines for HIV 1

Glycans Function as Anchors for Antibodies and Help Drive HIV Broadly Neutralizing Antibody Development

Volunteer motivators for participating in HIV vaccine clinical trials in Nairobi Kenya

Characterization of a stable HIV 1 B C recombinant soluble and trimeric envelope glycoprotein Env highly resistant to CD4 induced conformational changes

Fibroblast adapted human CMV vaccines elicit predominantly conventional CD8 T cell responses in humans

HIV 1 neutralizing antibody induced by simian adenovirus and poxvirus MVA vectored BG505 native like envelope trimers

Plasma CXCL13 but Not B Cell Frequencies in Acute HIV Infection Predicts Emergence of Cross Neutralizing Antibodies

Design and crystal structure of a native like HIV 1 envelope trimer that engages multiple broadly neutralizing antibody precursors in vivo

Sequential and Simultaneous Immunization of Rabbits with HIV 1 Envelope Glycoprotein SOSIP 664 Trimers from Clades A B and C

Development and validation of a risk score to assist screening for acute HIV 1 infection among men who have sex with men

A Comparative Phase I Study of Combination Homologous Subtype C DNA MVA and Env gp140 Protein Adjuvant HIV Vaccines in Two Immunization Regimes

A Prominent Site of Antibody Vulnerability on HIV Envelope Incorporates a Motif Associated with CCR5 Binding and Its Camouflaging Glycans

Early Antibody Lineage Diversification and Independent Limb Maturation Lead to Broad HIV 1 Neutralization Targeting the Env High Mannose Patch

Lactobacillus Deficient Cervicovaginal Bacterial Communities Are Associated with Increased HIV Acquisition in Young South African Women

Particulate Array of Well Ordered HIV Clade C Env Trimers Elicits Neutralizing Antibodies that Display a Unique V2 Cap Approach

Glycine Substitution at Helix to Coil Transitions Facilitates the Structural Determination of a Stabilized Subtype C HIV Envelope Glycoprotein

HIV Vaccine Design to Target Germline Precursors of Glycan Dependent Broadly Neutralizing Antibodies

Population attributable fraction of incident HIV infections associated with alcohol consumption in fishing communities around Lake Victoria Uganda

Identification and characterization of a naturally occurring efficiently cleaved membrane bound clade A HIV 1 Env suitable for immunogen design with properties comparable to membrane bound BG505

High prevalence of curable sexually transmitted infections among pregnant women in a rural county hospital in Kilifi Kenya

Heterogeneity of HIV incidence a comparative analysis between fishing communities and in a neighbouring rural general population Uganda and implications for HIV control

Novel approaches in preclinical HIV vaccine research

Promotion of couples voluntary HIV counseling and testing a comparison of influence networks in Rwanda and Zambia

Hepatitis B Virus Incidence and Risk Factors Among Human Immunodeficiency Virus 1 Negative Men Who Have Sex With Men in Kenya

Using facilitated film viewings to engage communities in HIV research involving MSM in Kenya

Evolution of B cell analysis and Env trimer redesign

An HIV 1 Env Antibody Complex Focuses Antibody Responses to Conserved Neutralizing Epitopes

Uptake and Acceptability of Oral HIV Self Testing among Community Pharmacy Clients in Kenya A Feasibility Study

Covalent Linkage of HIV 1 Trimers to Synthetic Liposomes Elicits Improved B Cell and Antibody Responses

High Resolution Longitudinal Study of HIV 1 Env Vaccine Elicited B Cell Responses to the Virus Primary Receptor Binding Site Reveals Affinity Maturation and Clonal Persistence

Impact of pre adapted HIV transmission

Linkage to HIV care after home based HIV counselling and testing in sub Saharan Africa a systematic review

Linkage to HIV care after home based HIV counselling and testing in sub Saharan Africa a systematic review (2)

Sustained effect of couples HIV counselling and testing on risk reduction among Zambian HIV serodiscordant couples

Balance between transmitted HLA preadapted and nonassociated polymorphisms is a major determinant of HIV 1 disease progression

Improving the Expression and Purification of Soluble Recombinant Native Like HIV 1 Envelope Glycoprotein Trimers by Targeted Sequence Changes

Reducing V3 Antigenicity and Immunogenicity on Soluble Native Like HIV 1 Env SOSIP Trimers

Single Virus Droplet Microfluidics for High Throughput Screening of Neutralizing Epitopes on HIV Particles

A shot at AIDS

Test and treat the early experiences in a clinic serving women at high risk of HIV infection in Kampala

Dengue and Chikungunya Virus Infections among Young Febrile Adults Evaluated for Acute HIV 1 Infection in Coastal Kenya

Differential Antibody Responses to Conserved HIV 1 Neutralizing Epitopes in the Context of Multivalent Scaffolds and Native Like gp140 Trimers

Fitting HIV Prevalence 1981 Onwards for Three Indian States Using the Goals Model and the Estimation and Projection Package

Lipid interactions and angle of approach to the HIV 1 viral membrane of broadly neutralizing antibody 10E8 Insights for vaccine and therapeutic design

Thermostability of Well Ordered HIV Spikes Correlates with the Elicitation of Autologous Tier 2 Neutralizing Antibodies

Moving towards a reliable HIV incidence test current status resources available future directions and challenges ahead

Semen Bacterial Concentrations and HIV 1 RNA Shedding Among HIV 1 Seropositive Kenyan Men

Minimally Mutated HIV 1 Broadly Neutralizing Antibodies to Guide Reductionist Vaccine Design

Stabilization of a soluble native like trimeric form of an efficiently cleaved Indian HIV 1 clade C envelope glycoprotein

Dual Immunity Concomitantly Suppresses HIV 1 Progression

First in Human Evaluation of the Safety and Immunogenicity of an Intranasally Administered Replication Competent Sendai Virus Vectored HIV Type 1 Gag Vaccine Induction of Potent T Cell or Antibody Responses in Prime Boost Regimens

Performance of the Bio Rad Geenius HIV1 2 Supplemental Assay in Detecting Recent HIV Infection and Calculating Population Incidence

A Phase 1 Study of 4 Live Recombinant Human Cytomegalovirus Towne Toledo Chimera Vaccines in Cytomegalovirus Seronegative Men

Health Provider Views on Improving Antiretroviral Therapy Adherence Among Men Who Have Sex with Men in Coastal Kenya

Assessment of Anti HIV 1 Antibodies in Oral and Nasal Compartments of Volunteers From 3 Different Populations

No Evidence for Association of Defensin Genomic Copy Number with HIV Susceptibility HIV Load during Clinical Latency or Progression to AIDS

Oral Typhoid Vaccination With Live Attenuated Salmonella Typhi Strain Ty21a Generates Ty21a Responsive and Heterologous Influenza Virus Responsive CD4 and CD8 T Cells at the Human Intestinal Mucosa

A Broadly Neutralizing Antibody Targets the Dynamic HIV Envelope Trimer Apex via a Long Rigidified and Anionic Hairpin Structure

Effects of partially dismantling the CD4 binding site glycan fence of HIV 1 Envelope glycoprotein trimers on neutralizing antibody induction

Diversification in the HIV 1 Envelope Hyper variable Domains V2 V4 and V5 and Higher Probability of Transmitted Founder Envelope Glycosylation Favor the Development of Heterologous Neutralization Breadth

HIV Controllers Exhibit Enhanced Frequencies of Major Histocompatibility Complex Class II Tetramer Gag Specific CD4 T Cells in Chronic Clade C HIV 1 Infection

Multiple Antibody Lineages in One Donor Target the Glycan V3 Supersite of the HIV 1 Envelope Glycoprotein and Display a Preference for Quaternary Binding

The plasma virome of febrile adult Kenyans shows frequent parvovirus B19 infections and a novel arbovirus Kadipiro virus

Membrane bound modified form of clade B Env JRCSF is suitable for immunogen design as it is efficiently cleaved and displays all the broadly neutralizing epitopes including V2 and C2 domain dependent conformational epitopes

HIV 1 clade C escapes broadly neutralizing autologous antibodies with N332 glycan specificity by distinct mechanisms

Dynamics and Correlates of CD8 T Cell Counts in Africans with Primary Human Immunodeficiency Virus Type 1 Infection

Hormonal Contraceptive Use Among HIV Positive Women and HIV Transmission Risk to Male Partners Zambia 1994 2012

Association of mutations in V3 C3 domain with enhanced sensitivity of HIV 1 clade C primary envelopes to autologous broadly neutralizing plasma antibodies

Cross neutralizing anti HIV 1 human single chain variable fragments scFvs against CD4 binding site and N332 glycan identified from a recombinant phage library

Virus driven Inflammation Is Associated With the Development of bNAbs in Spontaneous Controllers of HIV

Public community engagement in health research with men who have sex with men in sub Saharan Africa challenges and opportunities

Priming HIV 1 broadly neutralizing antibody precursors in human Ig loci transgenic mice

New Vaccines against Epidemic Infectious Diseases

Presenting native like trimeric HIV 1 antigens with self assembling nanoparticles

Uncleaved prefusion optimized gp140 trimers derived from analysis of HIV 1 envelope metastability

Trimeric HIV 1 Env Structures Define Glycan Shields from Clades A B and G

How intersectional constructions of sexuality culture and masculinity shape identities and sexual decision making among men who have sex with men in coastal Kenya

HIV 1 Vaccine elicited Antibodies Reverted to Their Inferred Naive Germline Reveal Associations between Binding Affinity and in vivo Activation

Composition and Antigenic Effects of Individual Glycan Sites of a Trimeric HIV 1 Envelope Glycoprotein

Conformational Epitope Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV 1 Clade C Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop

Increased Valency of Conserved mosaic Vaccines Enhances the Breadth and Depth of Epitope Recognition

Tailored Immunogens Direct Affinity Maturation toward HIV Neutralizing Antibodies

Sequential Immunization Elicits Broadly Neutralizing Anti HIV 1 Antibodies in Ig Knockin Mice

Induction of HIV Neutralizing Antibody Lineages in Mice with Diverse Precursor Repertoires

Deciphering the human antigenome

Mechanisms of escape from the PGT128 family of anti HIV broadly neutralizing antibodies

Comparison of HIV incidence estimated in clinical trial and observational cohort settings in a high risk fishing population in Uganda Implications for sample size estimates

Control of HIV 1 replication in vitro by vaccine induced human CD8 T cells through conserved subdominant Pol epitopes

Factors associated with dropout in a long term observational cohort of fishing communities around lake Victoria Uganda

Key gp120 Glycans Pose Roadblocks to the Rapid Development of VRC01 Class Antibodies in an HIV 1 Infected Chinese Donor

Broad HIV 1 inhibition in vitro by vaccine elicited CD8 T cells in African adults

Effect of Text Message Phone Call and In Person Appointment Reminders on Uptake of Repeat HIV Testing among Outpatients Screened for Acute HIV Infection in Kenya A Randomized Controlled Trial

Maturation Pathway from Germline to Broad HIV 1 Neutralizer of a CD4 Mimic Antibody

Antigen Specific Antibody Glycosylation Is Regulated via Vaccination

Targeted Isolation of Antibodies Directed against Major Sites of SIV Env Vulnerability

How I Wish This Thing Was Initiated 100 Years Ago Willingness to Take Daily Oral Pre Exposure Prophylaxis among Men Who Have Sex with Men in Kenya

Rhesus Macaque B Cell Responses to an HIV 1 Trimer Vaccine Revealed by Unbiased Longitudinal Repertoire Analysis

HIV 1 Specific CD8 T Cells Exhibit Limited Cross Reactivity during Acute Infection

Mucosal Humoral Immune Response to SIVmac239 nef Vaccination and Vaginal Challenge

CXCL13 is a plasma biomarker of germinal center activity

Deciphering the human immunome

Structure Guided Redesign Increases the Propensity of HIV Env To Generate Highly Stable Soluble Trimers

Presenting native like HIV 1 envelope trimers on ferritin nanoparticles improves their immunogenicity

Model Building and Refinement of a Natively Glycosylated HIV 1 Env Protein by High Resolution Cryoelectron Microscopy

Kenyan MSM no longer a hidden population

Targeted screening of at risk adults for acute HIV 1 infection in sub Saharan Africa

Depression substance abuse and stigma among men who have sex with men in coastal Kenya

Heterosexual behaviours among men who sell sex to men in coastal Kenya

Strengthening healthcare providers skills to improve HIV services for MSM in Kenya

Risk of sexual physical and verbal assaults on men who have sex with men and female sex workers in coastal Kenya

Changes in sexual risk behavior among MSM participating in a research cohort in coastal Kenya

Development and pilot testing of an intervention to promote care engagement and adherence among HIV positive Kenyan MSM

Assessment of the Safety and Immunogenicity of 2 Novel Vaccine Platforms for HIV 1 Prevention A Randomized Trial

Exploring the Potential Health Impact and Cost Effectiveness of AIDS Vaccine within a Comprehensive HIV AIDS Response in Low and Middle Income Countries

Innate Lymphoid Cells Are Depleted Irreversibly during Acute HIV 1 Infection in the Absence of Viral Suppression

Hormonal Contraception Pregnancy Breastfeeding and Risk of HIV Disease Progression Among Zambian Women

Emerging themes for sensitivity training modules of African healthcare workers attending to men who have sex with men a systematic review

Engineering and Characterization of a Fluorescent Native Like HIV 1 Envelope Glycoprotein Trimer

Use of Modern Family Planning Methods in Fishing Communities of Lake Victoria Uganda

A Systematic Review of the Inclusion or Exclusion of Women in HIV Research From Clinical Studies of Antiretrovirals and Vaccines to Cure Strategies

Crystallographic Identification of Lipid as an Integral Component of the Epitope of HIV Broadly Neutralizing Antibody 4E10

Fusion peptide of HIV 1 as a site of vulnerability to neutralizing antibody

The green shoots of a novel training programme progress and identified key actions to providing services to MSM at Kenyan health facilities

Broadly Neutralizing Antibody Responses in a Large Longitudinal Sub Saharan HIV Primary Infection Cohort

High Transmitter CD4 T Cell Count Shortly after the Time of Transmission in a Study of African Serodiscordant Couples

Chemical Cross Linking Stabilizes Native Like HIV 1 Envelope Glycoprotein Trimer Antigens

A Phase I Double Blind Placebo Controlled Randomized Study of the Safety and Immunogenicity of Electroporated HIV DNA with or without Interleukin 12 in Prime Boost Combinations with an Ad35 HIV Vaccine in Healthy HIV Seronegative African Adults

Affinity Maturation of a Potent Family of HIV Antibodies Is Primarily Focused on Accommodating or Avoiding Glycans

Recruitment and retention of women in fishing communities in HIV prevention research

Antibodies to a conformational epitope on gp41 neutralize HIV 1 by destabilizing the Env spike

HLA Class II Associated HIV Polymorphisms Predict Escape from CD4 T Cell Responses

Immunogenicity of Stabilized HIV 1 Envelope Trimers with Reduced Exposure of Non neutralizing Epitopes

Geographic and temporal trends in the molecular epidemiology and genetic mechanisms of transmitted HIV 1 drug resistance an individual patient and sequence level meta analysis

Knowledge of HIV serodiscordance transmission and prevention among couples in Durban South Africa

Glycan clustering stabilizes the mannose patch of HIV 1 and preserves vulnerability to broadly neutralizing antibodies

HIV 1 broadly neutralizing antibody precursor B cells revealed by germline targeting immunogen

Multiplexed highly accurate DNA sequencing of closely related HIV 1 variants using continuous long reads from single molecule real time sequencing

Schistosoma mansoni Infection in Ugandan Men Is Associated with Increased Abundance and Function of HIV Target Cells in Blood but Not the Foreskin A Cross sectional Study

Cryo EM structure of a native fully glycosylated cleaved HIV 1 envelope trimer

Structural Constraints Determine the Glycosylation of HIV 1 Envelope Trimers

An efficiently cleaved HIV 1 clade C Env selectively binds to neutralizing antibodies

Vaccine Elicited Tier 2 HIV 1 Neutralizing Antibodies Bind to Quaternary Epitopes Involving Glycan Deficient Patches Proximal to the CD4 Binding Site

Influences on the Design and Purification of Soluble Recombinant Native Like HIV 1 Envelope Glycoprotein Trimers

Cleavage independent HIV 1 Env trimers engineered as soluble native spike mimetics for vaccine design

Identification of Common Features in Prototype Broadly Neutralizing Antibodies to HIV Envelope V2 Apex to Facilitate Vaccine Design

Authors reply Hormonal contraceptives and HIV Hazards of pronouncing negative studies with low power

Comprehensive antigenic map of a cleaved soluble HIV 1 envelope trimer

Hormonal contraception does not increase women s HIV acquisition risk in Zambian discordant couples 1994 2012

Identification of CD4 Binding Site Dependent Plasma Neutralizing Antibodies in an HIV 1 Infected Indian Individual

A Phase I Double Blind Placebo Controlled Randomized Study of the Safety and Immunogenicity of an Adjuvanted HIV 1 Gag Pol Nef Fusion Protein and Adenovirus 35 Gag RT Int Nef Vaccine in Healthy HIV Uninfected African Adults

Implementation of couples voluntary HIV counseling and testing services in Durban South Africa

HIV vaccine induced sero reactivity a challenge for trial participants researchers and physicians

Implementation of an electronic fingerprint linked data collection system a feasibility and acceptability study among Zambian female sex workers

Immunogenetic influences on acquisition of HIV 1 infection consensus findings from two African cohorts point to an enhancer element in IL19 1q32 2

Vaccine Induced Simian Immunodeficiency Virus Specific CD8 T Cell Responses Focused on a Single Nef Epitope Select for Escape Variants Shortly after Infection

Understanding Adherence to Daily and Intermittent Regimens of Oral HIV Pre exposure Prophylaxis Among Men Who Have Sex with Men in Kenya

Magnitude and Kinetics of CD8 T Cell Activation during Hyperacute HIV Infection Impact Viral Set Point

Effect of seasonal variation on adult clinical laboratory parameters in Rwanda Zambia and Uganda implications for HIV biomedical prevention trials

Building the Human Vaccines Project strategic management recommendations and summary report of the 15 16 July 2014 business workshop

Design and structure of two HIV 1 clade C SOSIP 664 trimers that increase the arsenal of native like Env immunogens

HIV 1 non macrophage tropic R5 envelope glycoproteins are not more tropic for entry into primary CD4 T cells than envelopes highly adapted for macrophages

Incidence and predictors of attrition from antiretroviral care among adults in a rural HIV clinic in Coastal Kenya a retrospective cohort study

High incidence of HIV 1 infection in a general population of fishing communities around Lake Victoria Uganda

Crystal structure of the HIV neutralizing antibody 2G12 in complex with a bacterial oligosaccharide analog of mammalian oligomannose

High frequency of transmitted HIV 1 Gag HLA class I driven immune escape variants but minimal immune selection over the first year of clade C infection

An influenza vaccine pill can we swallow it

Toward a more accurate view of human B cell repertoire by next generation sequencing unbiased repertoire capture and single molecule barcoding

Transplanting supersites of HIV 1 vulnerability

Development of a duplex real time RT qPCR assay to monitor genome replication gene expression and gene insert stability during in vivo replication of a prototype live attenuated canine distemper virus vector encoding SIV gag

Computational design of protein antigens that interact with the CDR H3 loop of HIV broadly neutralizing antibody 2F5

Primate immune responses to HIV 1 Env formulated in the saponin based adjuvant AbISCO 100 in the presence or absence of TLR9 co stimulation

Transmitted virus fitness and host T cell responses collectively define divergent infection outcomes in two HIV 1 recipients

Well ordered trimeric HIV 1 subtype B and C soluble spike mimetics generated by negative selection display native like properties

Pregnancy incidence and correlates in a clinical trial preparedness study North West Province South Africa

Creating an African HIV clinical research and prevention trials network HIV prevalence incidence and transmission

The Potential Impact of Preventive HIV Vaccines in China Results and Benefits of a Multi Province Modeling Collaboration

Broad and persistent Gag specific CD8 T cell responses are associated with viral control but rarely drive viral escape during primary HIV 1 infection

Immunization for HIV 1 Broadly Neutralizing Antibodies in Human Ig Knockin Mice

Canine distemper virus neutralization activity is low in human serum and it is sensitive to an amino acid substitution in the hemagglutinin protein

Immunogenic Display of Purified Chemically Cross Linked HIV 1 Spikes

Diverse antibody genetic and recognition properties revealed following HIV 1 envelope glycoprotein immunization

An assessment of fishing communities around Lake Victoria Uganda as potential populations for future HIV vaccine efficacy studies an observational cohort study

Structural Repertoire of HIV 1 Neutralizing Antibodies Targeting the CD4 Supersite in 14 Donors

Optimizing parallel induction of HIV type 1 specific antibody and T cell responses by multicomponent subunit vaccines

Engaging young adult clients of community pharmacies for HIV screening in Coastal Kenya a cross sectional study

HIV 1 VACCINES Priming a broadly neutralizing antibody response to HIV 1 using a germline targeting immunogen

HIV 1 VACCINES HIV 1 neutralizing antibodies induced by native like envelope trimers

CD4 CD8 lymphocyte ratio as a quantitative measure of immunologic health in HIV 1 infection findings from an African cohort with prospective data

Prevalence Incidence and Clearance of Anogenital Warts in Kenyan Men Reporting High Risk Sexual Behavior Including Men Who Have Sex With Men

Acceptability and feasibility of repeated mucosal specimen collection in clinical trial participants in Kenya

The stem of vesicular stomatitis virus G can be replaced with the HIV 1 Env membrane proximal external region without loss of G function or membrane proximal external region antigenic properties

The immune space a concept and template for rationalizing vaccine development

HIV 1 receptor binding site directed antibodies using a VH1 2 gene segment orthologue are activated by Env trimer immunization

Replicative fitness of transmitted HIV 1 drives acute immune activation proviral load in memory CD4 T cells and disease progression

Independent assessment of candidate HIV incidence assays on specimens in the CEPHIA repository

A novel live attenuated vesicular stomatitis virus vector displaying conformationally intact functional HIV 1 envelope trimers that elicits potent cellular and humoral responses in mice

CD4 induced activation in a soluble HIV 1 Env trimer

Structural evolution of glycan recognition by a family of potent HIV antibodies

Recombinant HIV envelope trimer selects for quaternary dependent antibodies targeting the trimer apex

Two classes of broadly neutralizing antibodies within a single lineage directed to the high mannose patch of HIV envelope

Host genetics and immune control of HIV 1 infection fine mapping for the extended human MHC region in an African cohort

Long term follow up of study participants from prophylactic HIV vaccine clinical trials in Africa

Stable 293 T and CHO cell lines expressing cleaved stable HIV 1 envelope glycoprotein trimers for structural and vaccine studies

Comparing the novel method of assessing PrEP adherence exposure using hair samples to other pharmacologic and traditional measures

Failure of a novel rapid antigen and antibody combination test to detect antigen positive HIV infection in African adults with early HIV infection

Diagnosing acute and prevalent HIV 1 infection in young African adults seeking care for fever a systematic review and audit of current practice

HIV 1 testing of young febrile adults seeking care for fever in sub Sahara Africa

A next generation cleaved soluble HIV 1 Env trimer BG505 SOSIP 664 gp140 expresses multiple epitopes for broadly neutralizing but not non neutralizing antibodies

Acute HIV 1 infection is as common as malaria in young febrile adults seeking care in coastal Kenya

Hyperglycosylated stable core immunogens designed to present the CD4 binding site are preferentially recognized by broadly neutralizing antibodies

Vaccination with Gag Vif and Nef gene fragments affords partial control of viral replication after mucosal challenge with SIVmac239

Broad HIV epitope specificity and viral inhibition induced by multigenic HIV 1 adenovirus subtype 35 vector vaccine in healthy uninfected adults

Promiscuous glycan site recognition by antibodies to the high mannose patch of gp120 broadens neutralization of HIV

An evaluation of HIV elite controller definitions within a large seroconverter cohort collaboration

Broad and potent HIV 1 neutralization by a human antibody that binds the gp41 gp120 interface

Structure of 2G12 Fab2 in complex with soluble and fully glycosylated HIV 1 Env by negative stain single particle electron microscopy

Conformational dynamics of single HIV 1 envelope trimers on the surface of native virions

Structure and immune recognition of trimeric pre fusion HIV 1 Env

Development of broadly neutralizing antibodies from autologous neutralizing antibody responses in HIV infection

Vaccine elicited human T cells recognizing conserved protein regions inhibit HIV 1

Profiling human antibody responses by integrated single cell analysis

Characterization of neutrophil subsets in healthy human pregnancies

Development of a contemporary globally diverse HIV viral panel by the EQAPOL program

Development of a luciferase based viral inhibition assay to evaluate vaccine induced CD8 T cell responses

Host genetics and viral load in primary HIV 1 infection clear evidence for gene by sex interactions

Immune activation alters cellular and humoral responses to yellow fever 17D vaccine

Neurovirulence and immunogenicity of attenuated recombinant vesicular stomatitis viruses in nonhuman primates

CD4 mimetic small molecules sensitize human immunodeficiency virus to vaccine elicited antibodies

Determinants in V2C2 region of HIV 1 clade C primary envelopes conferred altered neutralization susceptibilities to IgG1b12 and PG9 monoclonal antibodies in a context dependent manner

Low antibody dependent cellular cytotoxicity responses in Zambians prior to HIV 1 intrasubtype C superinfection

HIV Type 1 transmission networks among men having sex with men and heterosexuals in Kenya

Short Communication Defining optimality of a test for recent infection for HIV incidence surveillance

HIV transmission Selection bias at the heterosexual HIV 1 transmission bottleneck

Maximising the effect of combination HIV prevention through prioritisation of the people and places in greatest need a modelling study

Safety adherence and acceptability of intermittent tenofovir emtricitabine as HIV pre exposure prophylaxis PrEP among HIV uninfected Ugandan volunteers living in HIV serodiscordant relationships a randomized clinical trial

Non immunogenicity of overlapping gag peptides pulsed on autologous cells after vaccination of HIV infected individuals

Structural delineation of a quaternary cleavage dependent epitope at the gp41 gp120 interface on intact HIV 1 Env trimers

Broadly neutralizing HIV antibodies define a glycan dependent epitope on the prefusion conformation of gp41 on cleaved envelope trimers

Disease progression by infecting HIV 1 subtype in a seroconverter cohort in sub Saharan Africa

Evaluation of an empiric risk screening score to identify acute and early HIV 1 infection among MSM in Coastal Kenya

The effects of somatic hypermutation on neutralization and binding in the PGT121 family of broadly neutralizing HIV antibodies

Developmental pathway for potent V1V2 directed HIV neutralizing antibodies

Adaptation of the African couples HIV testing and counseling model for men who have sex with men in the United States an application of the ADAPT ITT framework

Vaccines that stimulate T cell immunity to HIV 1 the next step

Accelerating the development of a safe and effective HIV vaccine HIV vaccine case study for the Decade of Vaccines

Willingness to participate in HIV vaccine efficacy trials among high risk men and women from fishing communities along Lake Victoria in Uganda

A randomised placebo controlled first in human study of a novel clade C therapeutic peptide vaccine administered ex vivo to autologous white blood cells in HIV infected individuals

Preventive and therapeutic applications of neutralizing antibodies to Human Immunodeficiency Virus Type 1 HIV 1

Evaluation of WHO screening algorithm for the presumptive treatment of asymptomatic rectal gonorrhoea and chlamydia infections in at risk MSM in Kenya

A human antibody to the CD4 binding site of gp120 capable of highly potent but sporadic cross clade neutralization of primary HIV 1

Vaccine elicited primate antibodies use a distinct approach to the HIV 1 primary receptor binding site informing vaccine redesign

Global panel of HIV 1 Env reference strains for standardized assessments of vaccine elicited neutralizing antibodies

Dynamics of viremia in primary HIV 1 infection in Africans insights from analyses of host and viral correlates

SIV antigen specific effects on immune responses induced by vaccination with DNA electroporation and plasmid IL 12

Proof of principle for epitope focused vaccine design

Syphilis treatment response among HIV discordant couples in Zambia and Rwanda

Fertility goal based counseling increases contraceptive implant and IUD use in HIV discordant couples in Rwanda and Zambia

Development of replication competent viral vectors for HIV vaccine delivery

Robust neutralizing antibodies elicited by HIV 1 JRFL envelope glycoprotein trimers in nonhuman primates

Challenges in providing counselling to MSM in highly stigmatized contexts results of a qualitative study from Kenya

WHO s new guidelines for antiretroviral treatment

Crystal structure of a soluble cleaved HIV 1 envelope trimer

Cryo EM structure of a fully glycosylated soluble cleaved HIV 1 envelope trimer

High HIV 1 prevalence risk behaviours and willingness to participate in HIV vaccine trials in fishing communities on Lake Victoria Uganda

Human circulating PD 1 CXCR3 CXCR5 memory Tfh cells are highly functional and correlate with broadly neutralizing HIV antibody responses

Cross sectional survey of treatment practices for urethritis at pharmacies private clinics and government health facilities in coastal Kenya many missed opportunities for HIV prevention

Influences on trimerization and aggregation of soluble cleaved HIV 1 SOSIP envelope glycoprotein

Membrane bound SIV envelope trimers are immunogenic in ferrets after intranasal vaccination with a replication competent canine distemper virus vector

Multidonor analysis reveals structural elements genetic determinants and maturation pathway for HIV 1 neutralization by VRC01 class antibodies

Chemical cross linking of HIV 1 Env for direct TLR7 8 ligand conjugation compromises recognition of conserved antigenic determinants

B cells from knock in mice expressing broadly neutralizing HIV antibody b12 carry an innocuous B cell receptor responsive to HIV vaccine candidates

Immune tolerance negatively regulates B cells in knock in mice expressing broadly neutralizing HIV antibody 4E10

Immune clearance of highly pathogenic SIV infection

Immune focusing and enhanced neutralization induced by HIV 1 gp140 chemical cross linking

Synthetic glycopeptides reveal the glycan specificity of HIV neutralizing antibodies

Molecular architecture of the uncleaved HIV 1 envelope glycoprotein trimer

Adherence to antiretroviral therapy and clinical outcomes among young adults reporting high risk sexual behavior including men who have sex with men in coastal Kenya

Independent expansion of epitope specific plasma cell responses upon HIV 1 envelope glycoprotein immunization

Viral escape from neutralizing antibodies in early subtype A HIV 1 infection drives an increase in autologous neutralization breadth

Structural basis for diverse N glycan recognition by HIV 1 neutralizing V1 V2 directed antibody PG16

Supersite of immune vulnerability on the glycosylated face of HIV 1 envelope glycoprotein gp120

Antibodies expose multiple weaknesses in the glycan shield of HIV

Rapid quantitative mapping of anti HIV type 1 envelope serum antibody specificities

High acceptability of HIV pre exposure prophylaxis but challenges in adherence and use qualitative insights from a phase I trial of intermittent and daily PrEP in at risk populations in Kenya

Short communication HIV type 1 transmitted drug resistance and evidence of transmission clusters among recently infected antiretroviral naive individuals from Ugandan fishing communities of Lake Victoria

Safety and immunogenicity of DNA prime and modified vaccinia ankara virus HIV subtype C vaccine boost in healthy adults

Safety and immunogenicity of DNA and MVA HIV 1 subtype C vaccine prime boost regimens a phase I randomised Trial in HIV uninfected Indian volunteers

Immunogenicity of seven new recombinant yellow fever viruses 17D expressing fragments of SIVmac239 Gag Nef and Vif in Indian rhesus macaques

Impact of long term contraceptive promotion on incident pregnancy a randomized controlled trial among HIV positive couples in Lusaka Zambia

Identification of an HIV 1 clade A envelope that exhibits broad antigenicity and neutralization sensitivity and elicits antibodies targeting three distinct epitopes

Mining the antibodyome for HIV 1 neutralizing antibodies with next generation sequencing and phylogenetic pairing of heavy light chains

Accelerating next generation vaccine development for global disease prevention

Cytomegalovirus vectors violate CD8 T cell epitope recognition paradigms

High HIV 1 incidence correlates of HIV 1 acquisition and high viral loads following seroconversion among MSM

A Multiplex Microsphere Based Immunoassay Increases the Sensitivity of SIV Specific Antibody Detection in Serum Samples and Mucosal Specimens Collected from Rhesus Macaques Infected with SIVmac239

Engineering HIV envelope protein to activate germline B cell receptors of broadly neutralizing anti CD4 binding site antibodies

Low prevalence of transmitted HIV type 1 drug resistance among antiretroviral naive adults in a rural HIV clinic in Kenya

Design of an Escherichia coli expressed HIV 1 gp120 fragment immunogen that binds to b12 and induces broad and potent neutralizing antibodies

Factors associated with herpes simplex virus type 2 incidence in a cohort of human immunodeficiency virus type 1 seronegative Kenyan men and women reporting high risk sexual behavior

Anticipated changes in sexual risk behaviour following vaccination with a low efficacy HIV vaccine survey results from a South African township

Asymmetric recognition of the HIV 1 trimer by broadly neutralizing antibody PG9

Rational HIV immunogen design to target specific germline B cell receptors

Delineating antibody recognition in polyclonal sera from patterns of HIV 1 isolate neutralization

Heterologous prime boost regimens using rAd35 and rMVA vectors elicit stronger cellular immune responses to HIV proteins than homologous regimens

HLA B 57 versus HLA B 81 in HIV 1 infection slow and steady wins the race

HIV 1 RNA may decline more slowly in semen than in blood following initiation of efavirenz based antiretroviral therapy

Role of transmitted Gag CTL polymorphisms in defining replicative capacity and early HIV 1 pathogenesis

Lymph node T cell responses predict the efficacy of live attenuated SIV vaccines

Molecular identification cloning and characterization of transmitted founder HIV 1 subtype A D and A D infectious molecular clones

Immunization of macaques with soluble HIV type 1 and influenza virus envelope glycoproteins results in a similarly rapid contraction of peripheral B cell responses after boosting

A Blueprint for HIV Vaccine Discovery

Cumulative impact of host and viral factors on HIV 1 viral load control during early infection

Structural insights into key sites of vulnerability on HIV 1 Env and influenza HA

A phase I double blind placebo controlled randomized study of a multigenic HIV 1 adenovirus subtype 35 vector vaccine in healthy uninfected adults

Broadly neutralizing antibodies against HIV 1 templates for a vaccine

Highly potent HIV specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo

Complex type N glycan recognition by potent broadly neutralizing HIV antibodies

Structure guided alterations of the gp41 directed HIV 1 broadly neutralizing antibody 2F5 reveal new properties regarding its neutralizing function

Optimization and qualification of an 8 color intracellular cytokine staining assay for quantifying T cell responses in rhesus macaques for pre clinical vaccine studies

Anti HIV B Cell lines as candidate vaccine biosensors

A DNA based candidate HIV vaccine delivered via in vivo electroporation induces CD4 responses toward the 4 7 binding V2 loop of HIV gp120 in healthy volunteers

Protection against high dose highly pathogenic mucosal SIV challenge at very low serum neutralizing titers of the antibody like molecule CD4 IgG2

Background morbidity in HIV vaccine trial participants from various geographic regions as assessed by unsolicited adverse events

Safety and adherence to intermittent pre exposure prophylaxis PrEP for HIV 1 in African men who have sex with men and female sex workers

HIV 1 neutralizing antibodies display dual recognition of the primary and coreceptor binding sites and preferential binding to fully cleaved envelope glycoproteins

Learning from Nature to design new biomolecules

Developing standards of care for HIV prevention research in developing countries a case study of 10 research centers in Eastern and Southern Africa

Broad and potent neutralization of HIV 1 by a gp41 specific human antibody

Influence of HAART on alternative reading frame immune responses over the course of HIV 1 infection

A short segment of the HIV 1 gp120 V1 V2 region is a major determinant of resistance to V1 V2 neutralizing antibodies

Early loss to follow up of recently diagnosed HIV infected adults from routine pre ART care in a rural district hospital in Kenya a cohort study

Subunit organization of the membrane bound HIV 1 envelope glycoprotein trimer

HIV epidemic in Asia optimizing and expanding vaccine development

Lineage specific differences between human and simian immunodeficiency virus regulation of gp120 trimer association and CD4 binding

A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield

A trivalent recombinant Ad5 gag pol nef vaccine fails to protect rhesus macaques from infection or control virus replication after a limiting dose heterologous SIV challenge

HIV vaccine development challenges and opportunities towards solving the HIV vaccine neutralizing antibody problem

Transactional sex and HIV understanding the gendered structural drivers of HIV in fishing communities in Southern Malawi

HIV incidence and prevalence among cohorts of women with higher risk behaviour in Bloemfontein and Rustenburg South Africa a prospective study

Promotion of couples voluntary HIV counselling and testing in Lusaka Zambia by influence network leaders and agents

Laboratory expansion to large scale international HIV preventive vaccine trials

Partial enzymatic deglycosylation preserves the structure of cleaved recombinant HIV 1 envelope glycoprotein trimers

Selective deactivation of serum IgG a general strategy for the enhancement of monoclonal antibody receptor interactions

High HIV incidence and socio behavioral risk patterns in fishing communities on the shores of Lake Victoria Uganda

BLyS mediated modulation of naive B cell subsets impacts HIV Env induced antibody responses

Successes and challenges of HIV prevention in men who have sex with men

Antiretroviral prophylaxis for HIV prevention in heterosexual men and women

Differences in HIV natural history among African and non African seroconverters in Europe and seroconverters in sub Saharan Africa

Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses

Emergence of fluoroquinolone resistance in Neisseria gonorrhoeae isolates from four clinics in three regions of Kenya

A nonfucosylated variant of the anti HIV 1 monoclonal antibody b12 has enhanced Fc RIIIa mediated antiviral activity in vitro but does not improve protection against mucosal SHIV challenge in macaques

A bacterial lipooligosaccharide that naturally mimics the epitope of the HIV neutralizing antibody 2G12 as a template for vaccine design

PGV04 an HIV 1 gp120 CD4 binding site antibody is broad and potent in neutralization but does not induce conformational changes characteristic of CD4

Unliganded HIV 1 gp120 core structures assume the CD4 bound conformation with regulation by quaternary interactions and variable loops

Genetic variations and heterosexual HIV 1 infection analysis of clustered genes encoding CC motif chemokine ligands

HIV type 1 in a rural coastal town in Kenya shows multiple introductions with many subtypes and much recombination

Isolation and characterization of T cells from semen

Determinants of the higher order association of the restriction factor TRIM5alpha and other tripartite motif TRIM proteins

Computational design of high affinity epitope scaffolds by backbone grafting of a linear epitope

An engineered mutant of HIV 1 gp120 formulated with adjuvant Quil A promotes elicitation of antibody responses overlapping the CD4 binding site

Neutralizing epitopes in the membrane proximal external region of HIV 1 gp41 are influenced by the transmembrane domain and the plasma membrane

Subtle alteration of residues including N linked glycans in V2 loop modulate HIV 1 neutralization by PG9 and PG16 monoclonal antibodies

Biochemically defined HIV 1 envelope glycoprotein variant immunogens display differential binding and neutralizing specificities to the CD4 binding site

DNA Ad5 vaccination with SIV epitopes induced epitope specific CD4 T cells but few subdominant epitope specific CD8 T cells

How can HIV type 1 Env immunogenicity be improved to facilitate antibody based vaccine development

Prevalence of seroconversion symptoms and relationship to set point viral load findings from a subtype C epidemic 1995 2009

Influence network effectiveness in promoting couples HIV voluntary counseling and testing in Kigali Rwanda

Enhanced HIV 1 neutralization by antibody heteroligation

Identifying at risk populations in Kenya and South Africa HIV incidence in cohorts of men who report sex with men sex workers and youth

Structure of HIV 1 gp120 V1 V2 domain with broadly neutralizing antibody PG9

Evidence against extracellular exposure of a highly immunogenic region in the C terminal domain of the simian immunodeficiency virus gp41 transmembrane protein

Intra and inter clade cross reactivity by HIV 1 Gag specific T cells reveals exclusive and commonly targeted regions implications for current vaccine trials

Disparate associations of HLA class I markers with HIV 1 acquisition and control of viremia in an African population

A novel self replicating chimeric lentivirus like particle

Diagnosis of latent tuberculosis infection among HIV discordant partners using interferon gamma release assays

Rapid development of glycan specific broad and potent anti HIV 1 gp120 neutralizing antibodies in an R5 SIV HIV chimeric virus infected macaque

Modeling the impact on the HIV epidemic of treating discordant couples with antiretrovirals to prevent transmission

Role of donor genital tract HIV 1 diversity in the transmission bottleneck

Env glycoprotein heterogeneity as a source of apparent synergy and enhanced cooperativity in inhibition of HIV 1 infection by neutralizing antibodies and entry inhibitors

Structure based design of a protein immunogen that displays an HIV 1 gp41 neutralizing epitope

International seroepidemiology of adenovirus serotypes 5 26 35 and 48 in pediatric and adult populations

HIV incidence and risk factors for acquisition in HIV discordant couples in Masaka Uganda an HIV vaccine preparedness study

Local residents trained as influence agents most effective in persuading African couples on HIV counseling and testing

Prevalence of specific neutralizing antibodies against Sendai virus in populations from different geographic areas implications for AIDS vaccine development using Sendai virus vectors

A passion for global vaccines

A prospective study of frequency and correlates of intimate partner violence among African heterosexual HIV serodiscordant couples

Seroprevalence predictors and estimated incidence of maternal and neonatal Herpes Simplex Virus type 2 infection in semi urban women in Kilifi Kenya

Functional stability of unliganded envelope glycoprotein spikes among isolates of human immunodeficiency virus type 1 HIV 1

A directed molecular evolution approach to improved immunogenicity of the HIV 1 envelope glycoprotein

Increased risk of HIV 1 transmission in pregnancy a prospective study among African HIV 1 serodiscordant couples

HIV and syphilis prevalence and associated risk factors among fishing communities of Lake Victoria Uganda

Helical peptide arrays for lead identification and interaction site mapping

A panel of IgG1 b12 variants with selectively diminished or enhanced affinity for Fc receptors to define the role of effector functions in protection against HIV

Broad neutralization coverage of HIV by multiple highly potent antibodies

Computation guided backbone grafting of a discontinuous motif onto a protein scaffold

A single amino acid substitution in the C4 region in gp120 confers enhanced neutralization of HIV 1 by modulating CD4 binding sites and V3 loop

In vivo electroporation enhances the immunogenicity of an HIV 1 DNA vaccine candidate in healthy volunteers

Prevalence and incidence of HIV in a rural community based HIV vaccine preparedness cohort in Masaka Uganda

The TRIM5 alpha genotype of rhesus macaques affects acquisition of simian immunodeficiency virus SIVsmE660 infection after repeated limiting dose intrarectal challenge

Enhanced control of pathogenic Simian immunodeficiency virus SIVmac239 replication in macaques immunized with an interleukin 12 plasmid and a DNA prime viral vector boost vaccine regimen

Role of TRIM5 RING domain E3 ubiquitin ligase activity in capsid disassembly reverse transcription blockade and restriction of simian immunodeficiency virus

Direct antibody access to the HIV 1 membrane proximal external region positively correlates with neutralization sensitivity

Human leukocyte antigen variants B 44 and B 57 are consistently favorable during two distinct phases of primary HIV 1 infection in sub Saharan Africans with several viral subtypes

Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding

Trimeric HIV 1 glycoprotein gp140 immunogens and native HIV 1 envelope glycoproteins display the same closed and open quaternary molecular architectures

Activity of broadly neutralizing antibodies including PG9 PG16 and VRC01 against recently transmitted subtype B HIV 1 variants from early and late in the epidemic

The contribution of HIV discordant relationships to new HIV infections a rebuttal

Most adults seek urgent healthcare when acquiring HIV 1 and are frequently treated for malaria in coastal Kenya

Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody

Measuring human T cell responses in blood and gut samples using qualified methods suitable for evaluation of HIV vaccine candidates in clinical trials

AIDS vaccines and preexposure prophylaxis is synergy possible

Knowledge and perceptions of couples voluntary counseling and testing in urban Rwanda and Zambia a cross sectional household survey

A chimeric HIV 1 envelope glycoprotein trimer with an embedded granulocyte macrophage colony stimulating factor GM CSF domain induces enhanced antibody and T cell responses

Characterization of a core fragment of the rhesus monkey TRIM5 protein

A randomized controlled trial to promote long term contraceptive use among HIV serodiscordant and concordant positive couples in Zambia

High prevalence of quinolone resistance in Neisseria gonorrhoeae in coastal Kenya

Performance of the Focus HerpeSelect 2 enzyme immunoassay for the detection of herpes simplex virus type 2 antibodies in seven African countries

Post prostatic massage fluid urine as an alternative to semen for studying male genitourinary HIV 1 shedding

Reasons for ineligibility in phase 1 and 2A HIV vaccine clinical trials at Kenya AIDS vaccine initiative KAVI Kenya

Pregnancy rates among female participants in phase I and phase IIA AIDS vaccine clinical trials in Kenya

Genital HIV 1 RNA predicts risk of heterosexual HIV 1 transmission

Indeterminate and discrepant rapid HIV test results in couples HIV testing and counselling centres in Africa

Synthesis and analysis of the membrane proximal external region epitopes of HIV 1

Ion mobility mass spectrometry for extracting spectra of N glycans directly from incubation mixtures following glycan release application to glycans from engineered glycoforms of intact folded HIV gp120

Profound early control of highly pathogenic SIV by an effector memory T cell vaccine

Viral linkage in HIV 1 seroconverters and their partners in an HIV 1 prevention clinical trial

Estimating HIV incidence among adults in Kenya and Uganda a systematic comparison of multiple methods

Equivalence of ELISpot assays demonstrated between major HIV network laboratories

Association of chemokine receptor gene CCR2 CCR5 haplotypes with acquisition and control of HIV 1 infection in Zambians

Behavioral and social science in HIV vaccine clinical research Workshop report

Immunotypes of a quaternary site of HIV 1 vulnerability and their recognition by antibodies

Effects of neighboring glycans on antibody carbohydrate interaction

The influence of informed consent content on study participants contraceptive knowledge and concerns

A robust high throughput assay to determine the phagocytic activity of clinical antibody samples

Exploring the condom gap is supply or demand the limiting factor condom access and use in an urban and a rural setting in Kilifi district Kenya

Structure based vaccine design in HIV blind men and the elephant

Beyond detuning 10 years of progress and new challenges in the development and application of assays for HIV incidence estimation

Transmitted HIV type 1 drug resistance among individuals with recent HIV infection in East and Southern Africa

Crystal structure of human antibody 2909 reveals conserved features of quaternary structure specific antibodies that potently neutralize HIV 1

HIV vaccines current status worldwide and in Africa

Lack of detectable HIV 1 specific CD8 T cell responses in Zambian HIV 1 exposed seronegative partners of HIV 1 positive individuals

Impact of a functional KIR2DS4 allele on heterosexual HIV 1 transmission among discordant Zambian couples

Safety and immunogenicity study of Multiclade HIV 1 adenoviral vector vaccine alone or as boost following a multiclade HIV 1 DNA vaccine in Africa

The hypervariable HIV 1 capsid protein residues comprise HLA driven CD8 T cell escape mutations and covarying HLA independent polymorphisms

Replicating viral vectors as HIV vaccines summary report from the IAVI sponsored satellite symposium at the AIDS vaccine 2009 conference

Vaccination with a modified vaccinia virus Ankara MVA vectored HIV 1 immunogen induces modest vector specific T cell responses in human subjects

Yeast elicited cross reactive antibodies to HIV Env glycans efficiently neutralize virions expressing exclusively high mannose N linked glycans

Simian immunodeficiency virus from the sooty mangabey and rhesus macaque is modified with O linked carbohydrate

Macaque long term nonprogressors resist superinfection with multiple CD8 T cell escape variants of simian immunodeficiency virus

The B cell response is redundant and highly focused on V1V2 during early subtype C infection in a Zambian seroconverter

Very few substitutions in a germ line antibody are required to initiate significant domain exchange

Variable loop glycan dependency of the broad and potent HIV 1 neutralizing antibodies PG9 and PG16

Antibody 2G12 recognizes di mannose equivalently in domain and nondomain exchanged forms but only binds the HIV 1 glycan shield if domain exchanged

Human leukocyte antigens and HIV type 1 viral load in early and chronic infection predominance of evolving relationships

Preexposure chemoprophylaxis for HIV prevention in men who have sex with men

Safety immunogenicity of tgAAC09 a recombinant adeno associated virus type 2 HIV 1 subtype C vaccine in India

Couples voluntary counselling and testing and nevirapine use in antenatal clinics in two African capitals a prospective cohort study

A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV 1 infected individuals

Elicitation of structure specific antibodies by epitope scaffolds

Scaffolding to build a rational vaccine design strategy

High prevalence of Chlamydia trachomatis and Neisseria gonorrhoeae infections among HIV 1 negative men who have sex with men in coastal Kenya

A nonself sugar mimic of the HIV glycan shield shows enhanced antigenicity

A phase 2 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 vaccine based on adeno associated virus

Passive neutralizing antibody controls SHIV viremia and enhances B cell responses in infant macaques

Polyreactivity increases the apparent affinity of anti HIV antibodies by heteroligation

The 2010 scientific strategic plan of the Global HIV Vaccine Enterprise

Expression system dependent modulation of HIV 1 envelope glycoprotein antigenicity and immunogenicity

HIV AIDS vaccines and alternate strategies for treatment and prevention

Polysaccharide mimicry of the epitope of the broadly neutralizing anti HIV antibody 2G12 induces enhanced antibody responses to self oligomannose glycans

Rational antibody based HIV 1 vaccine design current approaches and future directions

Macaques vaccinated with simian immunodeficiency virus SIVmac239Delta nef delay acquisition and control replication after repeated low dose heterologous SIV challenge

Fundamental difference in the content of high mannose carbohydrate in the HIV 1 and HIV 2 lineages

Design of a non glycosylated outer domain derived HIV 1 gp120 immunogen that binds to CD4 and induces neutralizing antibodies

Soluble HIV 1 Env trimers in adjuvant elicit potent and diverse functional B cell responses in primates

The renaissance in HIV vaccine development future directions

Envelope glycans of immunodeficiency virions are almost entirely oligomannose antigens

AIDS HIV A boost for HIV vaccine design

Crystal structure of PG16 and chimeric dissection with somatically related PG9 structure function analysis of two quaternary specific antibodies that effectively neutralize HIV 1

MHC heterozygote advantage in simian immunodeficiency virus infected Mauritian cynomolgus macaques

Structure and function of broadly reactive antibody PG16 reveal an H3 subdomain that mediates potent neutralization of HIV 1

Heterosexual HIV 1 transmission after initiation of antiretroviral therapy a prospective cohort analysis

Antibodies against Manalpha1 2 Manalpha1 2 Man oligosaccharide structures recognize envelope glycoproteins from HIV 1 and SIV strains

Subtype specific conservation of isoleucine 309 in the envelope V3 domain is linked to immune evasion in subtype C HIV 1 infection

Role of complex carbohydrates in human immunodeficiency virus type 1 infection and resistance to antibody neutralization

Phase 1 safety and immunogenicity evaluation of ADMVA a multigenic modified vaccinia Ankara HIV 1 B C candidate vaccine

Phase 1 safety and immunogenicity evaluation of ADVAX a multigenic DNA based clade C B HIV 1 candidate vaccine

Potent adaptive immune responses induced against HIV 1 gp140 and influenza virus HA by a polyanionic carbomer

Lack of complex N glycans on HIV 1 envelope glycoproteins preserves protein conformation and entry function

Haematological and biochemistry laboratory abnormalities associated with splenomegaly in asymptomatic adults in Masaka Uganda implications for HIV biomedical prevention trials

Anti gp41 antibodies cloned from HIV infected patients with broadly neutralizing serologic activity

Evaluation of HIV type 1 strains in men having sex with men and in female sex workers in Mombasa Kenya

Comparison of polyclonal expansion methods to improve the recovery of cervical cytobrush derived T cells from the female genital tract of HIV infected women

Donor and recipient envs from heterosexual human immunodeficiency virus subtype C transmission pairs require high receptor levels for entry

HIV type 1 from a patient with baseline resistance to CCR5 antagonists uses drug bound receptor for entry

Relationship between antibody 2F5 neutralization of HIV 1 and hydrophobicity of its heavy chain third complementarity determining region

A V3 loop dependent gp120 element disrupted by CD4 binding stabilizes the human immunodeficiency virus envelope glycoprotein trimer

Structure of HIV 1 gp120 with gp41 interactive region reveals layered envelope architecture and basis of conformational mobility

Daily acyclovir for HIV 1 disease progression in people dually infected with HIV 1 and herpes simplex virus type 2 a randomised placebo controlled trial

Accelerating HIV vaccine development

HIV Selectest enzyme immunoassay and rapid test ability to detect seroconversion following HIV 1 infection

Viral inhibition assay a CD8 T cell neutralization assay for use in clinical trials of HIV 1 vaccine candidates

Acyclovir and transmission of HIV 1 from persons infected with HIV 1 and HSV 2

Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane proximal external region protect against mucosal challenge by simian human immunodeficiency virus SHIVBa L

A Phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C modified vaccinia Ankara virus vaccine candidate in Indian volunteers

Influence of novel CD4 binding defective HIV 1 envelope glycoprotein immunogens on neutralizing antibody and T cell responses in nonhuman primates

Affordable in house antiretroviral drug resistance assay with good performance in non subtype B HIV 1

Vaccination with SIVmac239Deltanef activates CD4 T cells in the absence of CD4 T cell loss

Photoinduced family specific site selective cleavage of TIM barrel proteins

Structural basis of immune evasion at the site of CD4 attachment on HIV 1 gp120

Thiyl glycosylation of olefinic proteins S linked glycoconjugate synthesis

Accuracy of serological assays for detection of recent infection with HIV and estimation of population incidence a systematic review

Recent trends in clinical trials of vaccines to prevent HIV AIDS

HIV inactivation by cross linking of photo labeled anti retroviral compounds with HIV reverse transcriptase

Escape from autologous neutralizing antibodies in acute early subtype C HIV 1 infection requires multiple pathways

Adaptive mutations in a human immunodeficiency virus type 1 envelope protein with a truncated V3 loop restore function by improving interactions with CD4

Structure of the HIV 1 gp41 membrane proximal ectodomain region in a putative prefusion conformation

Broad and potent neutralizing antibodies from an African donor reveal a new HIV 1 vaccine target

Selective expansion of HIV 1 envelope glycoprotein specific B cell subsets recognizing distinct structural elements following immunization

Structure based stabilization of HIV 1 gp120 enhances humoral immune responses to the induced co receptor binding site

Heterosexual transmission of human immunodeficiency virus type 1 subtype C Macrophage tropism alternative coreceptor use and the molecular anatomy of CCR5 utilization

Evaluation and recommendations on good clinical laboratory practice guidelines for phase I III clinical trials

Broadly neutralizing human anti HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers

A conformational switch in human immunodeficiency virus gp41 revealed by the structures of overlapping epitopes recognized by neutralizing antibodies

Transitions to and from the CD4 bound conformation are modulated by a single residue change in the human immunodeficiency virus type 1 gp120 inner domain

Effective low titer antibody protection against low dose repeated mucosal SHIV challenge in macaques

Vector mediated gene transfer engenders long lived neutralizing activity and protection against SIV infection in monkeys

Neutralizing antibodies generated during natural HIV 1 infection good news for an HIV 1 vaccine

An African perspective on mucosal immunity and HIV 1

Soluble CD4 and CD4 mimetic compounds inhibit HIV 1 infection by induction of a short lived activated state

Is audio computer assisted self interview ACASI useful in risk behaviour assessment of female and male sex workers Mombasa Kenya

Biochemical and biophysical comparison of cleaved and uncleaved soluble trimeric HIV 1 envelope glycoproteins

Characteristics of HIV 1 discordant couples enrolled in a trial of HSV 2 suppression to reduce HIV 1 transmission the partners study

Human immunodeficiency virus type 1 elite neutralizers individuals with broad and potent neutralizing activity identified by using a high throughput neutralization assay together with an analytical selection algorithm

Sensitivity and specificity of HIV rapid tests used for research and voluntary counselling and testing

Genetic identity biological phenotype and evolutionary pathways of transmitted founder viruses in acute and early HIV 1 infection

Chemical modification of proteins at cysteine opportunities in chemistry and biology

Vaccine induced cellular responses control simian immunodeficiency virus replication after heterologous challenge

Efficient recovery of high affinity antibodies from a single chain Fab yeast display library

Adaptation of HIV 1 to human leukocyte antigen class I

HIV Immune memory downloaded

Broad diversity of neutralizing antibodies isolated from memory B cells in HIV infected individuals

HIV 1 and influenza antibodies seeing antigens in new ways

Evolution of HLA B 5703 HIV 1 escape mutations in HLA B 5703 positive individuals and their transmission recipients

Willingness to participate in preventive HIV vaccine trials in a community based cohort in south western Uganda

Community engagement in health research two decades of experience from a research project on HIV in rural Uganda

A method for identification of HIV gp140 binding memory B cells in human blood

Broad neutralization of human immunodeficiency virus type 1 HIV 1 elicited from human rhinoviruses that display the HIV 1 gp41 ELDKWA epitope

A yeast glycoprotein shows high affinity binding to the broadly neutralizing human immunodeficiency virus antibody 2G12 and inhibits gp120 interactions with 2G12 and DC SIGN

Lessons from IAVI 006 a phase I clinical trial to evaluate the safety and immunogenicity of the pTHr HIVA DNA and MVA HIVA vaccines in a prime boost strategy to induce HIV 1 specific T cell responses in healthy volunteers

Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge

Immunology Two in one designer antibodies

CLSI derived hematology and biochemistry reference intervals for healthy adults in eastern and southern Africa

Concordant proficiency in measurement of T cell immunity in human immunodeficiency virus vaccine clinical trials by peripheral blood mononuclear cell and enzyme linked immunospot assays in laboratories from three continents

Inflammatory genital infections mitigate a severe genetic bottleneck in heterosexual transmission of subtype A and C HIV 1

Replicating viral vectors as HIV vaccines Summary Report from IAVI Sponsored Satellite Symposium International AIDS Society Conference July 22 2007

The human immunodeficiency virus type 1 envelope spike of primary viruses can suppress antibody access to variable regions

Pirate primates in uncharted waters lymphocyte transfers in unrelated MHC matched macaques

Expanding research capacity and accelerating AIDS vaccine development in Asia

Analysis of neutralization specificities in polyclonal sera derived from human immunodeficiency virus type 1 infected individuals

Human immunodeficiency virus type 1 env trimer immunization of macaques and impact of priming with viral vector or stabilized core protein

Complete characterization of killer Ig like receptor KIR haplotypes in Mauritian cynomolgus macaques novel insights into nonhuman primate KIR gene content and organization

Antibodies against viruses passive and active immunization

Glycosylation of gp41 of simian immunodeficiency virus shields epitopes that can be targets for neutralizing antibodies

Neutralizing activity of antibodies to the V3 loop region of HIV 1 gp120 relative to their epitope fine specificity

Macaques vaccinated with live attenuated SIV control replication of heterologous virus

The impact of project closure on HIV incidence and mortality in a cohort of couples in Lusaka Zambia

Preparedness for AIDS vaccine trials in India

Importance of the V1 V2 loop region of simian human immunodeficiency virus envelope glycoprotein gp120 in determining the strain specificity of the neutralizing antibody response

Total synthesis revised structure and biological evaluation of biyouyanagin A and analogues thereof

Screening for genital and anorectal sexually transmitted infections in HIV prevention trials in Africa

Modified Kigali combined staging predicts risk of mortality in HIV infected adults in Lusaka Zambia

Reagent switchable stereoselective beta 1 2 mannoside mannosylation OH 2 of mannose is a privileged acceptor

Potent antibody mediated neutralization and evolution of antigenic escape variants of simian immunodeficiency virus strain SIVmac239 in vivo

Human leukocyte antigen class I genotypes in relation to heterosexual HIV type 1 transmission within discordant couples

Neutralizing antibody and anti retroviral drug sensitivities of HIV 1 isolates resistant to small molecule CCR5 inhibitors

Demand forecasting for preventive AIDS vaccines economic and policy dimensions

The relationship between alcohol consumption and unprotected sex among known HIV discordant couples in Rwanda and Zambia

Structure determination of an anti HIV 1 Fab 447 52D peptide complex from an epitaxially twinned data set

Allyl sulfides are privileged substrates in aqueous cross metathesis application to site selective protein modification

Allogeneic lymphocytes persist and traffic in feral MHC matched mauritian cynomolgus macaques

Regional differences in prevalence of HIV 1 discordance in Africa and enrollment of HIV 1 discordant couples into an HIV 1 prevention trial

Participation in two phase II prophylactic HIV vaccine trials in the UK

A glycoconjugate antigen based on the recognition motif of a broadly neutralizing human immunodeficiency virus antibody 2G12 is immunogenic but elicits antibodies unable to bind to the self glycans of gp120

HIV vaccine research the way forward

The influence of motivational messages on future planning behaviors among HIV concordant positive and discordant couples in Lusaka Zambia

Transmission of HIV 1 Gag immune escape mutations is associated with reduced viral load in linked recipients

Antibody elicited against the gp41 N heptad repeat NHR coiled coil can neutralize HIV 1 with modest potency but non neutralizing antibodies also bind to NHR mimetics

Safety and immunogenicity of recombinant low dosage HIV 1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara MVA in humans in East Africa

Efficient HIV 1 transmission from macrophages to T cells across transient virological synapses

Nonhuman primate models and the failure of the Merck HIV 1 vaccine in humans

The demographic profile of sero discordant couples enrolled in clinical research in Rwanda and Zambia

New heterosexually transmitted HIV infections in married or cohabiting couples in urban Zambia and Rwanda an analysis of survey and clinical data

HIV vaccine trials in India

Differentiation between isomeric triantennary N linked glycans by negative ion tandem mass spectrometry and confirmation of glycans containing galactose attached to the bisecting beta1 4 GlcNAc residue in N glycans from IgG

Baseline morbidity in 2 990 adult African volunteers recruited to characterize laboratory reference intervals for future HIV vaccine clinical trials

A peptide inhibitor of HIV 1 neutralizing antibody 2G12 is not a structural mimic of the natural carbohydrate epitope on gp120

Enhancement of HIV DNA vaccine immunogenicity by the NKT cell ligand alpha galactosylceramide

Toward an AIDS vaccine

Understanding HIV risks among men who have sex with men in Africa

Analysis of the human immunodeficiency virus type 1 gp41 membrane proximal external region arrayed on hepatitis B surface antigen particles

Making autoantibodies safe

Vaccine protection by live attenuated simian immunodeficiency virus in the absence of high titer antibody responses and high frequency cellular immune responses measurable in the periphery

Cross subtype antibody and cellular immune responses induced by a polyvalent DNA prime protein boost HIV 1 vaccine in healthy human volunteers

Targeting the carbohydrates on HIV 1 Interaction of oligomannose dendrons with human monoclonal antibody 2G12 and DC SIGN

Characterizing clearance of helper adenovirus by a clinical rAAV1 manufacturing process

N terminal substitutions in HIV 1 gp41 reduce the expression of non trimeric envelope glycoproteins on the virus

Broad HIV 1 neutralization mediated by CD4 binding site antibodies

A strategy for accelerating the development of preventive AIDS vaccines

Science medicine and research in the developing world a perspective

Promotion of couples voluntary counselling and testing for HIV through influential networks in two African capital cities

Enrollment and retention of HIV discordant couples in Lusaka Zambia

Evolution of couples voluntary counseling and testing for HIV in Lusaka Zambia

The challenges of eliciting neutralizing antibodies to HIV 1 and to influenza virus

Modeling how many envelope glycoprotein trimers per virion participate in human immunodeficiency virus infectivity and its neutralization by antibody

HIV 1 infection in high risk men who have sex with men in Mombasa Kenya

Adaptation of the human immunodeficiency virus type 1 envelope glycoproteins to new world monkey receptors

Amplified transmission of HIV 1 comparison of HIV 1 concentrations in semen and blood during acute and chronic infection

The impact of an AIDS vaccine in developing countries a new model and initial results

HIV 1 rational vaccine design molecular details of b12 gp120 complex structure

Structures of the CCR5 N terminus and of a tyrosine sulfated antibody with HIV 1 gp120 and CD4

Overestimation of the South African HIV incidence using the BED IgG assay

Fc receptor but not complement binding is important in antibody protection against HIV

Studies of a prophylactic HIV 1 vaccine candidate based on modified vaccinia virus Ankara MVA with and without DNA priming effects of dosage and route on safety and immunogenicity

Are you on the market a capture recapture enumeration of men who sell sex to men in and around Mombasa Kenya

Analysis of the neutralization breadth of the anti V3 antibody F425 B4e8 and re assessment of its epitope fine specificity by scanning mutagenesis

Scientific and policy challenges to development of an AIDS vaccine

Requirement for CD4 T cell help in maintenance of memory CD8 T cell responses is epitope dependent

A comparative immunogenicity study in rabbits of disulfide stabilized proteolytically cleaved soluble trimeric human immunodeficiency virus type 1 gp140 trimeric cleavage defective gp140 and monomeric gp120

Executive summary and recommendations from the WHO UNAIDS IAVI expert group consultation on Phase IIB TOC trials as a novel strategy for evaluation of preventive HIV vaccines 31 January 2 February 2006 IAVI New York USA

Investigating the utility of the HIV 1 BED capture enzyme immunoassay using cross sectional and longitudinal seroconverter specimens from Africa

An affinity enhanced neutralizing antibody against the membrane proximal external region of human immunodeficiency virus type 1 gp41 recognizes an epitope between those of 2F5 and 4E10

Antigenic and immunogenic study of membrane proximal external region grafted gp120 antigens by a DNA prime protein boost immunization strategy

Exploiting the defensive sugars of HIV 1 for drug and vaccine design

Specific amino acids in the N terminus of the gp41 ectodomain contribute to the stabilization of a soluble cleaved gp140 envelope glycoprotein from human immunodeficiency virus type 1

Structural definition of a conserved neutralization epitope on HIV 1 gp120

Structural basis of enhanced binding of extended and helically constrained peptide epitopes of the broadly neutralizing HIV 1 antibody 4E10

Endpoints and regulatory issues in HIV vaccine clinical trials lessons from a workshop

Male circumcision for HIV prevention in men in Rakai Uganda a randomised trial

Rapid real time detection of acute HIV infection in patients in Africa

Clinical experience with plasmid DNA and modified vaccinia virus Ankara vectored human immunodeficiency virus type 1 clade A vaccine focusing on T cell induction

A recombinant non pathogenic Leishmania vaccine expressing human immunodeficiency virus 1 HIV 1 Gag elicits cell mediated immunity in mice and decreases HIV 1 replication in human tonsillar tissue following exposure to HIV 1 infection

Putting it together AIDS and the millennium development goals

Estimating the demand for a preventive HIV vaccine why we need to do better Reliable estimates would help in achieving several policy and advocacy objectives

Novel approach for differential diagnosis of HIV infections in the face of vaccine generated antibodies utility for detection of diverse HIV 1 subtypes

The cost effectiveness of treating male trichomoniasis to avert HIV transmission in men seeking sexually transmitted disease care in Malawi

Inhibition of HIV Env binding to cellular receptors by monoclonal antibody 2G12 as probed by Fc tagged gp120

AIDS vaccine efficacy trials expand capacity and prioritize Throughout Africa Asia and Latin America state of the art clinics and laboratories exist where 4 years ago there were none

Polyvalent HIV 1 Env vaccine formulations delivered by the DNA priming plus protein boosting approach are effective in generating neutralizing antibodies against primary human immunodeficiency virus type 1 isolates from subtypes A B C D and E

Altered primary CD8 T cell response to a modified virus Ankara MVA vectored vaccine in the absence of CD4 T cell help

Induction of multifunctional human immunodeficiency virus type 1 HIV 1 specific T cells capable of proliferation in healthy subjects by using a prime boost regimen of DNA and modified vaccinia virus Ankara vectored vaccines expressing HIV 1 Gag coupled to

How do viral and host factors modulate the sexual transmission of HIV Can transmission be blocked

Phase I clinical trial safety of DNA and modified virus Ankara vectored human immunodeficiency virus type 1 HIV 1 vaccines administered alone and in a prime boost regime to healthy HIV 1 uninfected volunteers

Standardization of cytokine flow cytometry assays

HIV vaccine design insights from live attenuated SIV vaccines

Cytotoxic T lymphocyte escape does not always explain the transient control of simian immunodeficiency virus SIVmac239 viremia in adenovirus boosted and DNA primed Mamu A 01 positive rhesus macaques

Induction of human immunodeficiency virus type 1 specific T cells by a bluetongue virus tubule vectored vaccine prime recombinant modified virus Ankara boost regimen

Biodistribution and persistence of an MVA vectored candidate HIV vaccine in SIV infected rhesus macaques and SCID mice

Vaccine route dose and type of delivery vector determine patterns of primary CD8 T cell responses

Cytolytic T lymphocytes CTLs from HIV 1 subtype C infected Indian patients recognize CTL epitopes from a conserved immunodominant region of HIV 1 Gag and Nef

Intermittent low level viremia in very early primary HIV 1 infection

Determinants of enrollment in a preventive HIV vaccine trial hypothetical versus actual willingness and barriers to participation

Cross reactivity of anti HIV 1 T cell immune responses among the major HIV 1 clades in HIV 1 positive individuals from 4 continents

AIDS vaccine development perspectives challenges hopes

The private demand for an AIDS vaccine in Thailand

Collecting the essence of man semen collection for HIV transmission studies in sub Saharan Africa

Factors limiting the immunogenicity of HIV 1 gp120 envelope glycoproteins

Enhanced immunogenicity using an alphavirus replicon DNA vaccine against human immunodeficiency virus type 1

Analysis of the neutralizing antibody response elicited in rabbits by repeated inoculation with trimeric HIV 1 envelope glycoproteins

Anti human immunodeficiency virus type 1 HIV 1 antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane proximal external region of glycoprotein gp41 to neutralize HIV 1

Novel adeno associated virus vector vaccine restricts replication of simian immunodeficiency virus in macaques

Unwelcome guests with master keys how HIV enters cells and how it can be stopped

Vaccine development to prevent cytomegalovirus disease report from the National Vaccine Advisory Committee

A dominant role for CD8 T lymphocyte selection in simian immunodeficiency virus sequence variation

An AIDS vaccine no time to give up

Research and development of new vaccines against infectious diseases

Characterization of the outer domain of the gp120 glycoprotein from human immunodeficiency virus type 1

DNA vaccines against human immunodeficiency virus type 1

A novel approach for producing lentiviruses that are limited to a single cycle of infection

Heterologous human immunodeficiency virus type 1 priming boosting immunization strategies involving replication defective adenovirus and poxvirus vaccine vectors

Vaccine protection from CD4 T cell loss caused by simian immunodeficiency virus SIV mac251 is afforded by sequential immunization with three unrelated vaccine vectors encoding multiple SIV antigens

TRIM5alpha mediates the postentry block to N tropic murine leukemia viruses in human cells

Consequences of cytotoxic T lymphocyte escape common escape mutations in simian immunodeficiency virus are poorly recognized in naive hosts

A naphthyridine carboxamide provides evidence for discordant resistance between mechanistically identical inhibitors of HIV 1 integrase

Viral entry denied

HIV transmission closing all the doors

Engineering RENTA a DNA prime MVA boost HIV vaccine tailored for Eastern and Central Africa

N linked glycosylation in the CXCR4 N terminus inhibits binding to HIV 1 envelope glycoproteins

AIDS HIV Developing an AIDS vaccine need uncertainty hope

Mode of action for linear peptide inhibitors of HIV 1 gp120 interactions

Analysis of the HIV 1 gp41 specific immune response using a multiplexed antibody detection assay

Structural basis of tyrosine sulfation and VH gene usage in antibodies that recognize the HIV type 1 coreceptor binding site on gp120

Protective efficacy of a multicomponent vector vaccine in cynomolgus monkeys after intrarectal simian immunodeficiency virus challenge

Passive immunotherapy in simian immunodeficiency virus infected macaques accelerates the development of neutralizing antibodies

Elicitation of neutralizing antibodies with DNA vaccines expressing soluble stabilized human immunodeficiency virus type 1 envelope glycoprotein trimers conjugated to C3d

Neutralization sensitivity of a simian human immunodeficiency virus SHIV HXBc2P 3 2N isolated from an infected rhesus macaque with neurological disease

CD4 induced T 20 binding to human immunodeficiency virus type 1 gp120 blocks interaction with the CXCR4 coreceptor

Binding and susceptibility to postentry restriction factors in monkey cells are specified by distinct regions of the human immunodeficiency virus type 1 capsid

Impact of mutations in the coreceptor binding site on human immunodeficiency virus type 1 fusion infection and entry inhibitor sensitivity

Acute HIV revisited new opportunities for treatment and prevention

Recent advances in the development of HIV 1 vaccines using replication incompetent adenovirus vectors

Envelope glycoprotein determinants of increased entry in a pathogenic simian human immunodeficiency virus SHIV HXBc2P 3 2 passaged in monkeys

Prospects for an AIDS vaccine

Reversion of CTL escape variant immunodeficiency viruses in vivo

A human immunodeficiency virus 1 HIV 1 clade A vaccine in clinical trials stimulation of HIV specific T cell responses by DNA and recombinant modified vaccinia virus Ankara MVA vaccines in humans

Correlation between env V1 V2 region diversification and neutralizing antibodies during primary infection by simian immunodeficiency virus sm in rhesus macaques

Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a small molecule CCR5 inhibitor

Localized changes in the gp120 envelope glycoprotein confer resistance to human immunodeficiency virus entry inhibitors BMS 806 and 155

Repeated low dose mucosal simian immunodeficiency virus SIVmac239 challenge results in the same viral and immunological kinetics as high dose challenge a model for the evaluation of vaccine efficacy in nonhuman primates

The cytoplasmic body component TRIM5alpha restricts HIV 1 infection in Old World monkeys

Removal of N linked glycosylation sites in the V1 region of simian immunodeficiency virus gp120 results in redirection of B cell responses to V3

Public health A sound rationale needed for phase III HIV 1 vaccine trials

Use of a small molecule CCR5 inhibitor in macaques to treat simian immunodeficiency virus infection or prevent simian human immunodeficiency virus infection

HIV 1 entry and its inhibition

Evolution of coreceptor use and CD4 independence in envelope clones derived from SIVsm infected macaques

Mutations in the C3 region of human and simian immunodeficiency virus envelope have differential effects on viral infectivity replication and CD4 dependency

Epitope mapping and characterization of a novel CD4 induced human monoclonal antibody capable of neutralizing primary HIV 1 strains

Role of the gp120 inner domain beta sandwich in the interaction between the human immunodeficiency virus envelope glycoprotein subunits

Live viral vectors Semliki Forest virus

Thorny issues in the ethics of AIDS vaccine trials

The entry of entry inhibitors a fusion of science and medicine

Structure based targeted deglycosylation of HIV 1 gp120 and effects on neutralization sensitivity and antibody recognition

Assorted mutations in the envelope gene of simian immunodeficiency virus lead to loss of neutralization resistance against antibodies representing a broad spectrum of specificities

Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1

Dynamics of HIV viremia and antibody seroconversion in plasma donors implications for diagnosis and staging of primary HIV infection

Major histocompatibility complex class I alleles associated with slow simian immunodeficiency virus disease progression bind epitopes recognized by dominant acute phase cytotoxic T lymphocyte responses

Tyrosine sulfation of human antibodies contributes to recognition of the CCR5 binding region of HIV 1 gp120

Development of prophylactic AIDS vaccines the current state of affairs

Medicine The need for a global HIV vaccine enterprise

Cytolysis by CCR5 using human immunodeficiency virus type 1 envelope glycoproteins is dependent on membrane fusion and can be inhibited by high levels of CD4 expression

Effects of HIV type 1 envelope glycoprotein proteolytic processing on antigenicity

Hyperglycosylated mutants of human immunodeficiency virus HIV type 1 monomeric gp120 as novel antigens for HIV vaccine design

Redox triggered infection by disulfide shackled human immunodeficiency virus type 1 pseudovirions

Conformational changes in env oligomer induced by an antibody dependent on the V3 loop base

Genetic fate of recombinant adeno associated virus vector genomes in muscle

Construction and immunogenicity in a prime boost regimen of a Semliki Forest virus vectored experimental HIV clade A vaccine

A community randomized controlled trial to investigate impact of improved STD management and behavioural interventions on HIV incidence in rural Masaka Uganda trial design methods and baseline findings

Development of a DNA MVA HIVA vaccine for Kenya

Design and tests of an HIV vaccine

Generation of neutralizing activity against human immunodeficiency virus type 1 in serum by antibody gene transfer

Design and validation of an enzyme linked immunospot assay for use in clinical trials of candidate HIV vaccines

The HIV vaccine pipeline from preclinical to phase III

The quest for an AIDS vaccine is the CD8 T cell approach feasible

A DNA MVA based candidate human immunodeficiency virus vaccine for Kenya induces multi specific T cell responses in rhesus macaques

Initial lessons from public private partnerships in drug and vaccine development

HIV AIDS Vaccine Development Challenges Progress and Future Directions

HIV vaccine development for the world an idea whose time has come

About

Our Work

Our Science

Newsroom